Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta

An Inevitable Evolution
It is all about the pull and less about the push when it comes to delivering an effective and valuable message to physicians without comprising compliance. And the panelists and speakers attending the Center for Business Intelligence’s Premier Opinion Leader Management Systems conference in King of Prussia, PA, couldn’t agree more.
Over the next five years, if not much sooner, the evolution of sales, marketing, and medical affairs will dramatically shift. Speaking from a global prospective, Andreas Tsukada, associate director, sales operations, at UCB Pharma, said that a lot more coordination will be necessary. He noted that if leveraging KOL via the Internet works abroad, it might also be extended to the US as well.
Michael Schaffer, senior district manager, virology, at Abbott, believes that there will be fewer, more important KOLs (especially in the specialty marketplace) and less funding. As a result, pharma will be forced to do more with less, engaging MSLs instead of sales reps. However, it will be important to determine necessary roles for each organization, and go with that strategy. “The key is communication internally within an organization,†said Deb Kientop, president of MSL360.
Meanwhile, Dale Hagemeyer, research vice president of Gartner, cautioned that risks still apply with MSLs. “If it walks like a duck, it talks like a duck†was the analogy he used to describe the comparison of sales rep vs. MSL. In order to separate the two, organizations need to understand what is and what is not permissible in terms of on- and off-label discussions. Until then, credibility and value will continue to be the driving forces behind sales.
Last but certainly not least, pharma will need to keep abreast of the MSL’s changing role. Sivakumar Nadarajah, director of global CRM solutions at Cegedim Dendrite, points out the various roles of a MSL. He or she spends most of the time managing KOL relationships, performing research on KOLs, responding to medical inquiries, providing the commercial side of the company with knowledge, and collaborating internally (see above) with sales teams.
“All these activities are done either manually or using multiple applications,†says Nadarajah. “Providing a unified software platform so that all these activities can be tracked and co-coordinated in a reportable manner will not only help MSLs become efficient, but also help them provide management visibility into their activities.â€